Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 1, 2010, Pages 101-108

  Bonnefont, J P ^a   Bastin, J ^a   Laforet P ^b   Aubey, F ^a   Mogenet, A ^c   Romano, S ^c   Ricquier, D ^c   Gobin Limballe, S ^a   Vassault, A ^c   Behin, A ^b   Eymard, B ^b   Bresson, J L ^c   Djouadi, F ^a  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CREATINE KINASE; PALMITOYL COENZYME A;

ARTICLE; CARNITINE PALMITOYLTRANSFERASE 2 DEFICIENCY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; EXERCISE TOLERANCE; FATTY ACID OXIDATION; FEMALE; FOLLOW UP; HUMAN; INBORN ERROR OF METABOLISM; MALE; MUTATION; MYALGIA; MYOPATHY; ONSET AGE; PRIORITY JOURNAL; QUALITY OF LIFE; RHABDOMYOLYSIS; SHORT FORM 36;

ACTIVITIES OF DAILY LIVING; ACYL-COA DEHYDROGENASE, LONG-CHAIN; ADULT; ANTILIPEMIC AGENTS; BEZAFIBRATE; CARNITINE O-PALMITOYLTRANSFERASE; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; MUSCULAR DISEASES; OXIDATION-REDUCTION; OXYGEN CONSUMPTION; PAIN; PALMITOYL COENZYME A; PILOT PROJECTS; RHABDOMYOLYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953808955     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.55     Document Type: Article

References (36)

1. Gregersen, N., Andresen, B.S., Pedersen, C.B., Olsen, R.K., Corydon, T.J. & Bross, P. Mitochondrial fatty acid oxidation defects-remaining challenges. J. Inherit. Metab. Dis. 31, 643-657 (2008).
2. Bennett, M.J. Pathophysiology of fatty acid oxidation disorders. J. Inherit. Metab. Dis. (2009); e-pub ahead of print 10 October 2009.
3. Sigauke, E., Rakheja, D., Kitson, K. & Bennett, M.J. Carnitine palmitoyltransferase II defciency: a clinical, biochemical, and molecular review. Lab. Invest. 83, 1543-1554 (2003).
4. Bonnefont, J.P., Djouadi, F., Prip-Buus, C., Gobin, S., Munnich, A. & Bastin, J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol. Aspects Med. 25, 495-520 (2004).
5. Lee, C.H., Olson, P. & Evans, R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144, 2201-2207 (2003). (Pubitemid 36629867)
6. Tenenbaum, A., Motro, M. & Fisman, E.Z. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafbrate lessons. Cardiovasc. Diabetol. 4, 14 (2005).
7. Djouadi, F. et al. Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-defcient cultured skin fbroblasts by bezafbrate. Pediatr. Res. 54, 446-451 (2003).
8. Djouadi, F., Aubey, F., Schlemmer, D. & Bastin, J. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 defciency in human muscle cells. J. Clin. Endocrinol. Metab. 90, 1791-1797 (2005).
9. Bonnefont, J.P., Bastin, J., Behin, A. & Djouadi, F. Bezafbrate for an inborn mitochondrial beta-oxidation defect. N. Engl. J. Med. 360, 838-840 (2009).
10. Djouadi, F., Bonnefont, J.P., Munnich, A. & Bastin, J. Characterization of fatty acid oxidation in human muscle mitochondria and myoblasts. Mol. Genet. Metab. 78, 112-118 (2003).
11. Perneger, T.V., Leplège, A., Etter, J.F. & Rougemont, A. Validation of a French-language version of the MOS 36-Item Short Form Health Survey (SF-36) in young healthy adults. J. Clin. Epidemiol. 48, 1051-1060 (1995).
12. Van Vlies, N., Ferdinandusse, S., Turkenburg, M., Wanders, R.J. & Vaz, F.M. PPAR alpha-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation. Biochim. Biophys. Acta 1767, 1134-1142 (2007).
13. Luquet, S. et al. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie 86, 833-837 (2004).
14. Wang, Y.X. et al. Regulation of muscle fber type and running endurance by PPARdelta. PLoS Biol. 2, e294 (2004).
15. Bocher, V., Pineda-Torra, I., Fruchart, J.C. & Staels, B. PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann. N. Y. Acad. Sci. 967, 7-18 (2002).
16. Knopp, R.H. Drug treatment of lipid disorders. N. Engl. J. Med. 341, 498-511 (1999).
17. Gilde, A.J. & Van Bilsen, M. Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle. Acta Physiol. Scand. 178, 425-434 (2003).
18. Barish, G.D., Narkar, V.A. & Evans, R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 116, 590-597 (2006).
19. Gregersen, N. et al. Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplifed by acyl-CoA dehydrogenase defciencies, with special focus on genotype-phenotype relationship. Hum. Mutat. 18, 169-189 (2001).
20. Seneca, S. et al. A mitochondrial tRNA aspartate mutation causing isolated mitochondrial myopathy. Am. J. Med. Genet. A 137, 170-175 (2005).
21. Angelini, C., Federico, A., Reichmann, H., Lombes, A., Chinnery, P. & Turnbull, D. Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders. Eur. J. Neurol. 13, 923-929 (2006).
22. Gobin-Limballe, S. et al. Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase defciency by bezafbrate in patient fbroblasts: toward a genotype-based therapy. Am. J. Hum. Genet. 81, 1133-1143 (2007).
23. Bastin, J., Aubey, F., Rötig, A., Munnich, A. & Djouadi, F. Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct defciencies in patients' cells lacking its components. J. Clin. Endocrinol. Metab. 93, 1433-1441 (2008).
24. Risérus, U. et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57, 332-339 (2008).
25. Thuillier, L. et al. Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 (CPT2) defciency. Hum. Mutat. 21, 493-501 (2003).
26. Saudubray, J.M. et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J. Inherit. Metab. Dis. 22, 488-502 (1999).
27. Lowry, O.H., Rosebrough, N.J., Farr, A.L. & Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
28. Djouadi, F. et al. Bezafbrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in defcient fbroblasts and is a potential therapy for fatty acid oxidation disorders. Hum. Mol. Genet. 14, 2695-2703 (2005).
29. Brivet, M., Slama, A., Saudubray, J.M., Legrand, A. & Lemonnier, A. Rapid diagnosis of long chain and medium chain fatty acid oxidation disorders using lymphocytes. Ann. Clin. Biochem. 32 (Pt 2), 154-159 (1995).
30. Demaugre, F., Bonnefont, J.P., Colonna, M., Cepanec, C., Leroux, J.P. & Saudubray, J.M. Infantile form of carnitine palmitoyltransferase II defciency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II defciencies. J. Clin. Invest. 87, 859-864 (1991).
31. Gaist, D., Rodríguez, L.A., Huerta, C., Hallas, J. & Sindrup, S.H. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12, 565-569 (2001).
32. Mayer, O. Jr, Simon, J., Holubec, L., Pikner, R. & Subrt, I. Fenofbrate-induced hyperhomocysteinemia may be prevented by folate co-administration. Eur. J. Clin. Pharmacol. 59, 367-371 (2003).
33. Najib, J. Fenofbrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin. Ther. 24, 2022-2050 (2002).
34. Honig, P. & Lalonde, R. The economics of drug development: a grim reality and a role for clinical pharmacology. Clin. Pharmacol. Ther. 87, 247-251 (2010).
35. Kaitin, K.I. Deconstructing the drug development process: the new face of innovation. Clin. Pharmacol. Ther. 87, 356-361 (2010).
36. Porter, M.E. What is strategy? Harv. Bus. Rev. 61-78 (1996).